Tenapanor HCl

• CAT Number: I009752
• CAS Number: 1234365-97-9 (2HCl)
• Molecular Formula: C50H68Cl6N8O10S2
• Molecular Weight: 1217.96
• Purity: ≥95%
• Target: Na+/H+ exchanger 3 (NHE3) inhibitor
• Solubility: Soluble in DMSO and water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C50H66Cl4N8O10S2.2ClH/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-4
• InChIKey: VFRAXTZDILCRKY-OWRGXFNZSA-N
• SMILES: O=S(C1=CC=CC([C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)=C1)(NCCOCCOCCNC(NCCCCNC(NCCOCCOCCNS(=O)(C4=CC=CC([C@@H]5CN(C)CC6=C5C=C(Cl)C=C6Cl)=C4)=O)=O)=O)=O.[H]Cl.[H]Cl

Tenapanor HCl (CAT: I009752) is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3. NHE3 is involved in regulating sodium absorption and fluid balance in the gastrointestinal tract and kidneys. By inhibiting NHE3, tenapanor reduces sodium absorption, leading to increased excretion of sodium in the stool. This mechanism of action results in decreased intestinal sodium absorption, leading to potential therapeutic applications in conditions such as irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease.

Reference

1: Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study. Clin Pharmacol Drug Dev. 2017 Mar 24. doi: 10.1002/cpdd.341. [Epub ahead of print] PubMed PMID: 28339149.2: Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacol Drug Dev. 2017 Mar 16. doi: 10.1002/cpdd.346. [Epub ahead of print] PubMed PMID: 28301096.